Skip to main content
Boule Diagnostics logo

Boule Diagnostics — Investor Relations & Filings

Ticker · BOUL ISIN · SE0011231158 LEI · 213800IK1TGY858TKZ45 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2019-02-15 Major Shareholding Noti…
Country SE Sweden
Listing ST BOUL

About Boule Diagnostics

https://boule.com/

Boule Diagnostics is a global provider of diagnostic solutions specializing in hematology. The company develops, manufactures, and markets systems and consumables for blood diagnostics, including hematology analyzers, clinical chemistry analyzers, and associated reagents, controls, and calibrators. Its products are tailored for decentralized healthcare settings in both the human and veterinary markets, such as smaller laboratories and clinics. The company aims to enhance global healthcare access by providing high-quality instruments that deliver timely and accurate blood test results.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 1% confidence The document explicitly details a change in shareholding ('Holder: Handelsbanken Fonder AB') in Boule Diagnostic AB, showing the 'Before the transaction' and 'After the transaction' share counts and resulting percentages. The section 'Reason for major shareholding notification Sell' confirms this is a notification regarding a significant ownership change. This directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a structured report of ownership changes, not a general announcement of a report (RPA) or a general regulatory filing (RNS).
2019-02-15 English
Earnings Release 2018
Earnings Release Classification · 1% confidence The document is titled "Bokslutskommuniké januari–december 2018" (Year-end report communication January–December 2018) and contains detailed financial figures for the fourth quarter (oktober-december 2018) and the full year (januari-december 2018), including Net Sales, Gross Profit, Operating Result, and Earnings Per Share. It also includes a CEO's statement summarizing the year's activities and challenges (like the FDA warning letter) and proposing a dividend. This structure is characteristic of a comprehensive annual financial report or a year-end earnings release that often serves as the primary disclosure for the full fiscal year. Since it provides comprehensive financial details for the full year (R12) and is not merely a brief announcement of results, it aligns best with the Annual Report category (10-K), although the Swedish context suggests it might be the equivalent statutory annual report filing. Given the options, 10-K is the closest equivalent for a full-year financial disclosure. FY 2018
2019-02-07 Swedish
Boule Diagnostics investerar i ett strategiskt partnerskap inom patientnära diagnostik
M&A Activity Classification · 1% confidence The document announces a strategic partnership and investment by Boule Diagnostics into biosurfit, involving the acquisition of shares for 5 MEUR. This transaction concerns fundraising, capital structure changes (acquisition of equity), and strategic business development. This fits best under the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate financing event.
2018-12-14 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Boule Diagnostics AB for the period January–September 2018. It contains comprehensive financial statements, including income statements, cash flow analysis, regional/product sales breakdowns, and management commentary on business performance. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year. 9M 2018
2018-11-06 Swedish
Boule Diagnostics får varningsbrev från amerikanska myndigheten FDA
Legal Proceedings Report Classification · 1% confidence The document is a short announcement dated October 5, 2018, detailing that Boule Diagnostics received a warning letter from the US FDA regarding observations from a May 2018 inspection. It discusses the company's response, commitment to compliance, and confirms that production/sales are not restricted. The text explicitly states that this information is required to be made public under the EU Market Abuse Regulation. This type of communication, concerning regulatory actions, legal matters, or significant compliance issues that do not fit into standard financial reports (like 10-K or ER), is best classified as a Legal Proceedings Report (LTR) or, given its nature as a general regulatory disclosure, potentially a Regulatory Filing (RNS). Since it specifically addresses a formal regulatory action (FDA warning letter) and the resulting compliance steps, LTR is a strong fit. However, LTR is defined as 'Updates on significant lawsuits, regulatory actions, or legal matters involving the company.' This fits perfectly. It is not an ER, IR, or 10-K because it is an announcement about an action, not the financial results themselves. Given the specific nature of the FDA action, LTR is more precise than the general RNS fallback.
2018-10-05 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Boule Diagnostics AB for the period January–June 2018. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on business performance, which fits the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full financial data and analysis. H2 2018
2018-08-15 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.